Introduction: Unraveling a Viral Weakness
For decades, scientists have struggled to develop treatments for a broad family of viruses that cause everything from the common cold to paralytic polio. Enteroviruses—which include poliovirus, coxsackievirus, echovirus, and rhinoviruses—are responsible for millions of infections worldwide each year. Now, researchers at the University of Maryland, Baltimore County (UMBC) have exposed a critical vulnerability shared by these pathogens. In a study published in Nature Communications, they revealed in unprecedented detail how enteroviruses control their replication inside human cells, uncovering what they describe as a molecular on-off switch. This discovery could open the door to broad-spectrum antiviral drugs.
Understanding Enteroviruses: A Formidable Family
Enteroviruses are small, positive-sense single-stranded RNA viruses. Their genetic material acts both as a messenger RNA (for protein synthesis) and as a template for replication. Once inside a host cell, the virus must decide whether to translate its RNA into proteins (including the machinery needed to build new virus particles) or to copy its genome to produce more RNA copies. This decision is crucial: if the virus makes too many proteins too early, it may run out of material for replication; if it replicates too much without making enough capsid proteins, no infectious particles can assemble.
Until now, the molecular details of how this balance is achieved remained obscure. The UMBC team, led by virologist Dr. Rachel L. Thompson, focused on a specific region of the viral RNA called the internal ribosome entry site (IRES), which is known to be essential for starting protein synthesis in many viruses.
The Molecular On-Off Switch: How Viral RNA Recruits Host and Viral Proteins
Using cryo-electron microscopy and advanced biochemical assays, the researchers captured snapshots of the IRES in action. They observed that the viral RNA forms a complex three-dimensional structure that can bind simultaneously to both human proteins (such as polypyrimidine tract-binding protein, PTB) and viral proteins (like RNA-dependent RNA polymerase).
Critically, the team identified a conformational change in the IRES that acts as a switch. When human PTB protein binds to the IRES, the RNA structure shifts into a configuration that favors translation—the production of viral proteins. But when viral polymerase binds to a different part of the RNA, the switch flips, promoting genome replication instead. This elegant mechanism ensures that the virus doesn't misallocate its limited resources.
How the Discovery Was Made
The research involved inserting specific mutations into the IRES of a model enterovirus and monitoring the effect on replication. We were amazed to see that a single nucleotide change could completely disrupt the switch,
said Dr. Thompson. This tells us that the region is a precisely tuned control point.
The team then used structural biology to visualize the RNA-protein interactions at near-atomic resolution.
Implications for Antiviral Therapy
Because the switch mechanism relies on both viral and host components that are conserved across many enteroviruses, it represents a weak spot that could be targeted by new drugs. Currently, there are no approved antivirals that work against the entire enterovirus family. Polio has been nearly eradicated by vaccines, but wild poliovirus still circulates in a few countries, and vaccine-derived strains can cause outbreaks. Meanwhile, enteroviruses like EV-D68 have caused severe respiratory illness and acute flaccid myelitis in children.
- Broad-spectrum potential: A drug that locks the switch in either the translation or replication state could halt viral reproduction.
- Reduced resistance risk: Because the switch involves both viral RNA and host proteins, mutations that evade a drug would likely weaken the virus.
- Existing drug repositioning: Some compounds that bind to RNA structures are already in clinical trials for other diseases.
Next Steps for Research
Dr. Thompson’s lab is now screening small molecules that can interfere with the switch. They are also collaborating with medicinal chemists to design compounds that mimic the effect of the viral polymerase binding site. If we can disrupt the balance, the virus will effectively kill itself,
she remarked.
In addition, the team plans to investigate whether other RNA viruses—such as those causing hepatitis C or dengue—use similar switches. If so, the findings could have even wider implications.
Conclusion: A Common Cold Cure in Sight?
While a cure for the common cold is still a distant goal, this discovery provides a powerful new avenue for developing treatments against many enterovirus infections. The elegant molecular switch that controls viral replication is now laid bare, and scientists have a clear target for the first time. As research continues, we may soon see antiviral therapies that work against polio, myocarditis, encephalitis, and yes, even the common cold.
Note: This article is based on the original press release from the University of Maryland, Baltimore County, published in [journal] and reported on [date].